Archives

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
Filter by categories:
Meet the top guns steering MediKane in food-as-medicine space
Featured zone

Meet the top guns steering MediKane in food-as-medicine space

Highlights,MediKane aims to become a dominant player in the safe plant-based ‘Food-as-Medicine’ health space.,The company’s products target common global chronic health conditions.,MediKane is guided by a highly skilled and experienced team.,MediKane,is a...

How does EarlyBirds help various enterprises implement and benefit from data-driven innovations?
Featured zone

How does EarlyBirds help various enterprises implement and benefit from data-driven innovations?

Highlights,EarlyBirds helps businesses tap into innovations in various aspects of data management and analytics globally.,Data has been called the oil of the digital era and can be used by organisations to develop an enormous competitive advantage and dri...

Vertex Minerals (ASX:VTX) discovers multiple pegmatite intersections at Taylors Rock Project
Featured zone

Vertex Minerals (ASX:VTX) discovers multiple pegmatite intersections at Taylors Rock Project

Highlights,Vertex Minerals (ASX:VTX) has discovered several unassayed pegmatite intersections via a review of drill logs at the Taylors Rock Project.,The Taylors Rock Nickel Gold Project has not been subjected to any previous exploration for lithium.,VTX ...

GQG’s (ASX:GQG) FUM falls in September; what’s the reason?
Financial Stocks

GQG’s (ASX:GQG) FUM falls in September; what’s the reason?

Shares of GQG are trading in red today. According to GQG's media release, FUM of the company dropped in September.

Radiopharm (ASX:RAD) hails release of DUNP19 cancer study in prestigious scientific journal
Featured zone

Radiopharm (ASX:RAD) hails release of DUNP19 cancer study in prestigious scientific journal

Highlights,The prominent scientific journal ‘Nature’ has published an authoritative analysis of the role of LRRC15 in cancer growth.,The article highlights that LRRC15 proteins on cancer-associated fibroblasts (CAFs) protect tumour cells from the immune s...

Imugene’s (ASX:IMU) HERIZON study results to feature at ESMO Asia Congress
Sponsored

Imugene’s (ASX:IMU) HERIZON study results to feature at ESMO Asia Congress

Highlights,Imugene Limited will be giving an oral presentation of an abstract about the overall survival results from its HER-Vaxx HERIZON study at the ESMO Asia Congress 2022,The event will be held from 2-4 December in Singapore,Principal investigator Ma...

  • October 07, 2022 02:37 PM AEDT
  • Manisha
Bolstered portfolio, advanced clinical programs: Chimeric (ASX:CHM) sees action-packed FY22
Featured zone

Bolstered portfolio, advanced clinical programs: Chimeric (ASX:CHM) sees action-packed FY22

Highlights,Chimeric substantially bolstered its portfolio and advanced clinical development during FY22.,The period saw the licensing of a novel CAR T cell therapy from the University of Pennsylvania.,The company continued to advance its first asset in a ...

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK